Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures

• Published in: Frontiers in molecular biosciences Vol. 8; p. 759495
• Main Authors: Ji, Fei, Yuan, Jiao-Mei, Gao, Hong-Fei, Xu, Ai-Qi, Yang, Zheng, Yang, Ci-Qiu, Zhang, Liu-Lu, Yang, Mei, Li, Jie-Qing, Zhu, Teng, Cheng, Min-Yi, Wu, Si-Yan, Wang, Kun
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 11.10.2021
• Subjects: biomarker; breast cancer; Molecular Biosciences; neoadjuvant chemotherapy; prognosis; stromal immunotype
• ISSN: 2296-889X; 2296-889X
• DOI: 10.3389/fmolb.2021.759495

Immune response which involves distinct immune cells is associated with prognosis of breast cancer. Nonetheless, less study have determined the associations of different types of immune cells with patient survival and treatment response. In this study, A total of 1,502 estrogen receptor(ER)-negative breast cancers from public databases were used to infer the proportions of 22 subsets of immune cells. Another 320 ER-negative breast cancer patients from Guangdong Provincial People’s Hospital were also included and divided into the testing and validation cohorts. CD8 + T cells, CD4 + T cells, B cells, and M1 macrophages were associated with favourable outcome (all p <0.01), whereas Treg cells were strongly associated with poor outcome ( p = 0.005). Using the LASSO model, we classified patients into the stromal immunotype A and B subgroups according to immunoscores. The 10 years OS and DFS rates were significantly higher in the immunotype A subgroup than immunotype B subgroup. Stromal immunotype was identified as an independent prognostic indicator in multivariate analysis in all cohorts and was also related to pathological complete response(pCR) after neoadjuvant chemotherapy. The nomogram that integrated the immunotype and clinicopathologic features showed good predictive accuracy for pCR and discriminatory power. The stromal immunotype A subgroup had higher expression levels of immune checkpoint molecules (PD-L1, PD-1, and CTLA-4) and cytokines (IL-2, INF-γ, and TGF-β). In addition, patients with immunotype A and B diseases had distinct mutation signatures. Therefore, The stromal immunotypes could predict survival and responses of ER-negative breast cancer patients to neoadjuvant chemotherapy.